American College of Emergency Physicians  
Clinical Policies Committee Meeting  
May 30-31, 2019  
ACEP Headquarters, Irving, TX  

MINUTES

Participants

Committee members participating in all or part of the meeting: Stephen J. Wolf, MD, FACEP, Chair; Richard Bynny, MD, MSc, FACEP, Methodologist (by phone); Stephen V. Cantrill, MD, FACEP, Liaison with Quality and Patient Safety Committee, and the E-QUAL Steering Committee; Christopher R. Carpenter, MD, FACEP; Deborah B. Diercks, MD, MSc, FACEP; Seth R. Gemme, MD; Charles J. Gerardo, MD, MHS, FACEP; Steven A. Godwin, MD, FACEP; Sigrid A. Hahn, MD, MPH (by phone); Nicholas E. Harrison, MD, EMRA Representative (by phone); Benjamin W. Hatten, MD, MPH; Jason S. Haukoos, MD, MSc, FACEP, Methodologist (by phone); Jon Mark Hirshon, MD, PhD, MPH, FACEP, Board Liaison; Amy Kaji, MD, MPH, PhD, Methodologist; Heemun Kwok, MD, MS, Methodologist; Bruce M. Lo, MD, MBA, RDMS, FACEP; Sharon E. Mace, MD, FACEP, FAAP; Devorah J. Nazarian, MD; Jean A. Proehl, RN MN, CEN, CPEN, TCRN, FAEN, FAAN, ENA Representative; Susan B. Promes, MD, MBA, FACEP; Kausbal H. Shah, MD, FACEP; Richard D. Shih, MD, FACEP; Scott M. Silvers, MD, FACEP; Michael D. Smith, MD, MBA, FACEP; Molly E.W. Thiessen, MD; Christian A. Tomaszewski, MD, MS, MBA, FACEP; Jonathan H. Valente, MD, FACEP; Stephen P. Wall, MD, MSc, MAEd, Methodologist.

Also present for all or part of the meeting: Eric M. Ketcham, MD, FACEP, Subcommittee on Opioids (by phone); Brandon Maughan, MD, MSH, MSHP, FACEP, Subcommittee on Community-Acquired Pneumonia (by phone); Daniel P. Runde, MD, FACEP, Subcommittee on Opioids (by phone); Yanling Yu, PhD, Advocate for Patient Safety; Travis Schulz, MLS, AHIP, Staff Liaison; and Rhonda R. Whitson, RHIA, Staff Liaison.

Agenda

1. Welcome and introductions
2. Disclosures pertinent to the agenda
3. Review opioid clinical policy draft
4. Discuss blunt trauma draft critical questions
5. Social media
6. Review latest community-acquired pneumonia draft
7. Preliminary objectives 2019-2020
8. Guideline update
9. Liaison reports/Other

Major Points Discussed

1. Welcome and introductions
   
   Dr. Wolf welcomed everyone to the meeting. Participants introduced themselves.

2. New disclosures pertinent to the agenda
   
   There were no disclosures pertinent to the agenda.
3. Review opioid clinical policy draft

Dr. Cantrill opened the discussion by reviewing the proposed National Quality Forum Measure #3316e, Safe Use of Opioids – Concurrent Prescribing, with the Committee. The Committee had a lengthy discussion of the measure and what it would mean for emergency medicine. Dr. Hatten then led the discussion of the opioid draft with assistance from Dr. Cantrill, Dr. Ketcham, and Dr. Runde. The Committee suggested edits to the draft. The subcommittee will incorporate the suggested changes and the Committee will review the revised draft.

4. Discuss blunt trauma draft critical questions

Dr. Gerardo led the discussion on the draft acute blunt trauma critical questions. The Committee had a lengthy discussion of the draft questions. The subcommittee will refine the draft critical questions and the Committee will review the revised questions.

5. Social media

Dr. Harrison presented the posts on the venous thromboembolism clinical policy that were made April 16, 2019 from ACEP’s Twitter, Instagram, and Facebook accounts. The Committee discussed the posts and the desire to continue posting clinical policy content. Clinical Policies Committee staff will confer with ACEP Member Communications regarding the continuation, frequency, management, and tagging of the future posts.

6. Review latest community-acquired pneumonia draft

Dr. Smith led the discussion of the community-acquired pneumonia draft with assistance from subcommittee members, Dr. Mace and Dr. Maughan. The Committee suggested edits to the draft. The subcommittee will incorporate the suggested changes and the Committee will review the revised draft.

7. Preliminary objectives 2019-2020

Dr. Wolf led the discussion of the preliminary objectives for 2019-2020. The Committee discussed the possibility of proposing a policy statement on emergency medicine’s scope of practice in acute trauma. The proposed objective will be discussed with the Incoming President.

8. Guideline update

Dr. Harrison provided an overview of the guideline titled “Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America (IDSA)”. Dr. Harrison will prepare a summary of the guideline for ACEP Now. Dr. Silvers will serve as his mentor for preparing the summary.

9. Liaison reports/Other

Dr. Wolf (liaison with the ACEP Clinical Resources Review Committee) provided a brief report on that Committee’s work.

Dr. Tomaszewski (liaison with the Education Committee) provided a brief update on that Committee’s work.
Dr. Cantrill (liaison with the Quality and Patient Safety Committee and the E-QUAL Steering Committee) provided a brief report on the current work of these groups.

Dr. Yu provided a report on her work with the National Quality Forum Patient Safety Advisory Committee and the Agency for Healthcare Research and Quality Committee on Diagnostic Error.

Dr. Silvers reported on his liaison activities with the American Heart Association Cardiovascular Care Committee and their work on the AHA’s strategic impact goals, resuscitation guidelines, and cardiac arrest identification.

Ms. Proehl (ENA Representative) gave an update on the current activities of the Emergency Nurses Association.

Dr. Hatten reported on his work with the American Dental Association and the International Union of Toxicology.

Drs. Dierks, Gemme, Harrison, Hatten, Mace, Shih, Tomaszewski, Valente, and Wolf provided updates on their work with the various American College of Radiology appropriateness criteria panels on which they serve.

Dr. Carpenter provided an update on plans by Academic Emergency Medicine to develop guideline-type products that would be different from ACEP’s clinical policies.